BioCryst Pharmaceuticals | BCRX - Interest Expense On Debt

Stock Price
9.57
Daily Change
-0.11 -1.09%
Monthly
2.85%
Yearly
32.48%
Q2 Forecast
9.30

BioCryst Pharmaceuticals reported $14.14M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Chugai Pharma JPY 95M 260M Dec/2025
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
DBV Technologies USD 461K 323.71K Mar/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novavax USD 5.82M 342K Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025